Inhibition of myeloid derived suppressor cells migration to the tumor microenvironment enhances PD1-checkpoint blockade therapy. This image relates to a paper that appeared in the May 21, 2014, issue of Science Translational Medicine, published by AAAS. The paper, by Dr. S.L. Highfill at the National Cancer Institute, National Institutes of Health in Bethesda, Md., and colleagues was titled, "Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy."
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact Science for permission.